Letters To The Editor
Copyright ©2013 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Hepatol. Oct 27, 2013; 5(10): 601-602
Published online Oct 27, 2013. doi: 10.4254/wjh.v5.i10.601
A correction of misinformation regarding Herbalife
Kristy Appelhans, Raushanah Najeeullah, Vasilios Frankos
Kristy Appelhans, Raushanah Najeeullah, Vasilios Frankos, Department of Global Product Science Safety and Compliance, Herbalife International of America Inc, Torrance, CA 90502, United States
Author contributions: Appelhans K, Najeeullah R, and Frankos V analyzed the subject article and each contributed to the content of the letter.
Correspondence to: Kristy Appelhans, ND, Director, Department of Global Product Science Safety and Compliance, Herbalife International of America Inc, 990 W 190th Street Suite 650, Torrance, CA 90502, United States. kristyr@herbalife.com
Telephone: +1-310-7192458 Fax: +1-310-7673375
Received: October 26, 2012
Revised: March 19, 2013
Accepted: October 11, 2013
Published online: October 27, 2013
Processing time: 364 Days and 0.9 Hours
Core Tip

Core tip: The authors of the subject article by Senadhi et al have misrepresented the safety and regulatory status of Herbalife’s products. Most importantly, the authors have misinformed the readership that Food and Drug Administration (FDA) has taken action against Herbalife for its known association with reports of liver injury. FDA has taken no action on the company for this reason or any other reasons to date.